Holen Sie sich die Stockscreener-App
123.52
1.96%
2.37
Handel nachbörslich:
124.30
0.78
+0.63%
Schlusskurs vom Vortag:
$121.15
Offen:
$120.65
24-Stunden-Volumen:
292.01K
Relative Volume:
0.53
Marktkapitalisierung:
$6.16B
Einnahmen:
$338.46M
Nettoeinkommen (Verlust:
$-310.96M
KGV:
-18.92
EPS:
-6.53
Netto-Cashflow:
$-132.82M
1W Leistung:
+4.11%
1M Leistung:
+4.31%
6M Leistung:
+19.31%
1J Leistung:
+44.60%
1-Tages-Spanne:
$120.12
$124.39
1-Wochen-Bereich:
$117.30
$124.39
52-Wochen-Spanne:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Firmenname
Axsome Therapeutics Inc
Sektor
Branche
Telefon
(212) 332-3241
Adresse
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Vergleichen Sie AXSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
123.52 | 6.05B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-01 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-03 | Fortgesetzt | Wells Fargo | Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-04-07 | Eingeleitet | Jefferies | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-31 | Bestätigt | Mizuho | Outperform |
| 2024-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2024-08-06 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-04-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2024-01-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-08-08 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Eingeleitet | Piper Sandler | Neutral |
| 2022-11-01 | Eingeleitet | Loop Capital | Buy |
| 2022-09-07 | Fortgesetzt | Mizuho | Buy |
| 2021-08-10 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Eingeleitet | Berenberg | Buy |
| 2021-01-08 | Eingeleitet | Jefferies | Buy |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-09-29 | Eingeleitet | BofA Securities | Underperform |
| 2020-09-10 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-04-28 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-14 | Eingeleitet | Cowen | Outperform |
| 2019-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-17 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-16 | Bestätigt | Guggenheim | Buy |
| 2019-10-16 | Eingeleitet | Guggenheim | Buy |
| 2019-09-18 | Eingeleitet | William Blair | Outperform |
| 2019-05-28 | Eingeleitet | SunTrust | Buy |
| 2019-05-23 | Bestätigt | H.C. Wainwright | Buy |
| 2019-04-08 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-15 | Bestätigt | H.C. Wainwright | Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2015-12-15 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-12-14 | Eingeleitet | Ladenburg Thalmann | Buy |
Alle ansehen
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
What candlestick patterns are forming on Axsome Therapeutics Inc.Analyst Downgrade & Precise Swing Trade Entry Alerts - newser.com
Axsome Therapeutics Inc. stock volume spike explainedShare Buyback & AI Powered Market Entry Ideas - newser.com
How Axsome Therapeutics Inc. stock compares to market leadersFed Meeting & AI Powered Buy and Sell Recommendations - newser.com
Will Axsome Therapeutics Inc. (19X) stock deliver stable dividendsMarket Movers & Fast Entry Momentum Trade Alerts - newser.com
Is Axsome Therapeutics Inc. stock gaining market shareDip Buying & Fast Gain Swing Trade Alerts - newser.com
Axsome Therapeutics Inc. stock trend forecast2025 Geopolitical Influence & Proven Capital Preservation Methods - newser.com
Tools to assess Axsome Therapeutics Inc.’s risk profileQuarterly Risk Review & Long-Term Capital Growth Strategies - newser.com
Axsome Therapeutics (AXSM) Stock Analysis: Unpacking A Potential 45% Upside In Biotech - DirectorsTalk Interviews
Axsome Therapeutics, Inc. $AXSM Shares Sold by Blair William & Co. IL - MarketBeat
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Grows Stock Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
IFP Advisors Inc Sells 4,096 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 EPS Estimate for Axsome Therapeutics Reduced by Analyst - MarketBeat
Can trapped investors hope for a rebound in Axsome Therapeutics Inc.Gap Up & Verified Stock Trade Ideas - newser.com
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,590,330.30 in Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) CEO Sells $1,518,062.16 in Stock - MarketBeat
Herriot Tabuteau Sells 19,220 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Axsome Therapeutics (AXSM): Exploring Valuation After Recent Share Price Stability - Yahoo Finance
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community - The Manila Times
Real time social sentiment graph for Axsome Therapeutics Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
1 in 5 U.S. adults affected — Axsome Recognizes Mental Illness Awareness Week and shares NAMI resources - Stock Titan
Axsome therapeutics CEO sells $5.4m in shares By Investing.com - Investing.com Canada
Axsome therapeutics CEO sells $5.4m in shares - Investing.com
Leerink Partnrs Issues Positive Forecast for AXSM Earnings - MarketBeat
Axsome Therapeutics Schedule Third Quarter 2025 Financial Results Announcement and Conference Call - Quiver Quantitative
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - The Manila Times
Knights of Columbus Asset Advisors LLC Grows Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast - Stock Titan
Is Axsome Therapeutics Inc 19X a good long term investmentVolatility Adjusted Trading & Free Trading Psychology Sessions - earlytimes.in
Can Axsome Therapeutics Inc. stock withstand economic slowdownWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
Will Axsome Therapeutics Inc. (19X) stock outperform global peersM&A Rumor & High Conviction Trade Alerts - newser.com
J. Safra Sarasin Holding AG Purchases 9,998 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Meet Herriot Tabuteau, The Haitian-Born Doctor Whose Brain Disorder Medications Turned Into A $6 Billion Empire - Black Enterprise
What is B. Riley's Estimate for AXSM Q3 Earnings? - MarketBeat
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation - Yahoo Finance
Migraine Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories - Barchart.com
Axsome Therapeutics (NASDAQ:AXSM) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation - Nasdaq
AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | A - GuruFocus
How Axsome Therapeutics Inc. (19X) stock trades after rate cuts2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
B. Riley Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $179 - 富途牛牛
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN
H.C. Wainwright maintains Axsome stock Buy rating, $190 target - MSN
14 Best Biotech Stocks to Buy Right Now - Insider Monkey
Can Auvelity Drive Axsome's Growth Through the Rest of 2025? - The Globe and Mail
Obstructive Sleep Apnea Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma - Barchart.com
Obstructive Sleep Apnea Market Insights Highlight Expanding - openPR.com
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years - Mitrade
Finanzdaten der Axsome Therapeutics Inc-Aktie (AXSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Axsome Therapeutics Inc-Aktie (AXSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Option Exercise |
8.02 |
13,390 |
107,388 |
20,619 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Option Exercise |
8.02 |
12,774 |
102,447 |
20,003 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 06 '25 |
Sale |
120.17 |
19,220 |
2,309,667 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 07 '25 |
Sale |
118.77 |
13,390 |
1,590,330 |
7,229 |
| TABUTEAU HERRIOT | Chief Executive Officer |
Oct 08 '25 |
Sale |
118.84 |
12,774 |
1,518,062 |
7,229 |
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):